On Sunday, August 30th, the Broad Institute of MIT and Harvard performed its one-millionth test for Covid-19, reports Jonathan Saltzman for The Boston Globe. “Six months after the nonprofit institute in Cambridge began testing for the coronavirus to help overwhelmed laboratories and hospitals, the Broad reached the landmark as technicians, many of them recently hired, work around the clock,” writes Saltzman.
WBUR’s Carey Goldberg explores how MIT researchers developed a new CRISPR-based research tool that can be used to detect Covid-19. "A lot of things that we try fail," says research scientist Jonathan Gootenberg. "And that’s OK. Because sometimes you find these things that are really, really awesome."
Reporting for WBUR, Carey Goldberg highlights how MIT researchers have developed a new RNA editing tool that could be used to tweak a gene that raises the risk of Alzheimer’s disease. As the effects of RNA editing are not permanent, “it's almost like a small, pill-like version of gene therapy,” explains research scientist and McGovern Fellow Omar Abudayyeh.
Broad Institute postdoctoral associate Joshua Weinstein has developed a DNA microscope that allows researchers to investigate the locations and identity of DNA molecules, reports Sharon Begley for STAT. “Weinstein has so far used it to image human cancer cell lines and plans to apply the technology to tumors and the immune cells that infiltrate them,” writes Begley, “which might one day guide immunotherapy.”
Axios reporter Eileen Drage O’Reilly highlights how Prof. Feng Zhang and his colleagues have developed a new system that uses “jumping genes” to improve the accuracy of gene editing. “This is filling a gap we couldn't address before, to be able to insert DNA into the genome," says Zhang of the ability to insert large genomes in a directed way.
Researchers from MIT and other institutions have developed a new model for autism research that could enable new therapies and treatments, reports the Xinhua news agency. The model could “provide a basis for a deeper understanding of the neurobiological mechanisms of autism and the development of more transformative therapeutics.”
STAT reporter Sharon Begley writes that Prof. Feng Zhang and his colleagues have turned “a jumping gene — aka a transposon, or mobile genetic element — into a mini TaskRabbit gig worker: With an assist from CRISPR enzymes, it zips over to the part of the genome whose address it is given and delivers a package of DNA, pronto.”
Dr. Sekar Kathiresan, a member of the Broad Institute of MIT and Harvard, speaks with NPR’s Richard Harris about his work on an experimental genetic scan that could identify people who are likely to become severely overweight. “This work hopefully will destigmatize obesity and make it very similar to every other disease, which is a combination of both lifestyle and genetics,” said Kathiresan.
TIME reporter Alice Park writes that in a Nature commentary, an international group of scientists has called for a temporary ban on studies using gene-editing on human embryos. “Our question is, how should nations make decisions about technologies like gene editing going forward?” says Prof. Eric Lander, director of the Broad Institute and one of the authors of the commentary.
Associated Press reporter Malcom Ritter writes that an international team of scientists – including a number of MIT researchers – has called for a moratorium on making babies with genetically engineered DNA. “The moratorium would allow time for discussion of technical, scientific, societal and ethical issues that must be considered,” explains Ritter.
Financial Times reporter Hannah Kuchler writes that researchers from MIT and a number of other institutions have called for a moratorium on editing inheritable human genes. Kuchler writes that the researchers called for the establishment of “an international framework on the conditions in which such editing could be allowed.”
Prof. Aviv Regev speaks with the Associated Press about the Human Cell Atlas Consortium, which is aimed at cataloging all the cells in the human body in an effort to better understand human diseases. "This is not going to cure all disease immediately," she says, but "it is a critical stepping stone."
MIT researchers developed a new technique to make a more effective and precise CRISPR gene editing system, reports Eileen Drage O’Reilly for Axios. The system uses the new enzyme Cas12b, which has a “small size and precise targeting [that] will enable it to be used for in vivo applications in primary human cells,” O’Reilly explains.
Prof. Aviv Regev speaks with NPR’s Nell Greenfieldboyce about her work with the Human Cell Atlas trying to catalogue every cell in the human body. “We don't need to analyze every individual cell out of 37 trillion because the cells kind of repeat themselves,” says Regev. “All we need to do is sample enough of them from enough region in order to get comprehensive coverage.”
Writing for The Boston Globe, Prof. Eric Lander, president of the Broad Institute, argues for enabling cancer patients to become actively involved in cancer research. “Patients must have an active voice in decisions. Patient data should never be sold,” Lander writes. “Researchers anywhere should have rapid access to the de-identified clinical and genomic data, to ensure that anyone can make discoveries.”